Anti-interleukin-6 monoclonal antibody for cytokine storm in COVID-19

Novel coronavirus disease 2019 (COVID-19) is known to cause severe pneumonia and acute respiratory distress syndrome which may lead to death. Several treatments have been tested in the race to find a treatment regimen for this deadly viral infection. Tocilizumab, a recombinant humanized anti-interle...

Descripción completa

Detalles Bibliográficos
Autores principales: Douedi, Steven, Chaudhri, Moiuz, Miskoff, Jeffrey
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7423207/
https://www.ncbi.nlm.nih.gov/pubmed/32831940
http://dx.doi.org/10.4103/atm.ATM_286_20
_version_ 1783570135205806080
author Douedi, Steven
Chaudhri, Moiuz
Miskoff, Jeffrey
author_facet Douedi, Steven
Chaudhri, Moiuz
Miskoff, Jeffrey
author_sort Douedi, Steven
collection PubMed
description Novel coronavirus disease 2019 (COVID-19) is known to cause severe pneumonia and acute respiratory distress syndrome which may lead to death. Several treatments have been tested in the race to find a treatment regimen for this deadly viral infection. Tocilizumab, a recombinant humanized anti-interleukin-6 receptor monoclonal antibody, has been used and found to be beneficial in patients with COVID-19 and in cytokine storm. We present the case of a young, otherwise healthy male, presenting with COVID-19 and successfully treated in the intensive care unit with tocilizumab.
format Online
Article
Text
id pubmed-7423207
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Wolters Kluwer - Medknow
record_format MEDLINE/PubMed
spelling pubmed-74232072020-08-20 Anti-interleukin-6 monoclonal antibody for cytokine storm in COVID-19 Douedi, Steven Chaudhri, Moiuz Miskoff, Jeffrey Ann Thorac Med Case Report Novel coronavirus disease 2019 (COVID-19) is known to cause severe pneumonia and acute respiratory distress syndrome which may lead to death. Several treatments have been tested in the race to find a treatment regimen for this deadly viral infection. Tocilizumab, a recombinant humanized anti-interleukin-6 receptor monoclonal antibody, has been used and found to be beneficial in patients with COVID-19 and in cytokine storm. We present the case of a young, otherwise healthy male, presenting with COVID-19 and successfully treated in the intensive care unit with tocilizumab. Wolters Kluwer - Medknow 2020 2020-06-18 /pmc/articles/PMC7423207/ /pubmed/32831940 http://dx.doi.org/10.4103/atm.ATM_286_20 Text en Copyright: © 2020 Annals of Thoracic Medicine http://creativecommons.org/licenses/by-nc-sa/4.0 This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Case Report
Douedi, Steven
Chaudhri, Moiuz
Miskoff, Jeffrey
Anti-interleukin-6 monoclonal antibody for cytokine storm in COVID-19
title Anti-interleukin-6 monoclonal antibody for cytokine storm in COVID-19
title_full Anti-interleukin-6 monoclonal antibody for cytokine storm in COVID-19
title_fullStr Anti-interleukin-6 monoclonal antibody for cytokine storm in COVID-19
title_full_unstemmed Anti-interleukin-6 monoclonal antibody for cytokine storm in COVID-19
title_short Anti-interleukin-6 monoclonal antibody for cytokine storm in COVID-19
title_sort anti-interleukin-6 monoclonal antibody for cytokine storm in covid-19
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7423207/
https://www.ncbi.nlm.nih.gov/pubmed/32831940
http://dx.doi.org/10.4103/atm.ATM_286_20
work_keys_str_mv AT douedisteven antiinterleukin6monoclonalantibodyforcytokinestormincovid19
AT chaudhrimoiuz antiinterleukin6monoclonalantibodyforcytokinestormincovid19
AT miskoffjeffrey antiinterleukin6monoclonalantibodyforcytokinestormincovid19

Ejemplares similares